Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Not Confirmed
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Not Confirmed
Not Confirmed
05-08 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Industry Trade Show
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Industry Trade Show
Not Confirmed
05-08 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
19 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress-302560722.html
02 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/evommune-announces-late-breaker-presentation-of-phase-2-data-for-evo756-in-chronic-inducible-urticaria-at-upcoming-european-academy-of-dermatology-and-venereology-eadv-2025-congress-302543319.html
28 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/evommune-to-participate-in-three-upcoming-investor-conferences-302540687.html
27 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/evommune-initiates-phase-2b-trial-of-its-oral-mrgprx2-antagonist-evo756-in-adults-with-moderate-to-severe-atopic-dermatitis-302539614.html
28 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/evommune-announces-top-line-data-from-phase-2-trial-of-evo756-in-chronic-inducible-urticaria-demonstrating-robust-activity-and-favorable-safety-profile-302466088.html
15 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/evommune-initiates-phase-2b-trial-of-mrgprx2-antagonist-evo756-in-adults-with-moderate-to-severe-chronic-spontaneous-urticaria-302428672.html
ABOUT THIS PAGE